| Zacks Company Profile for Viatris Inc. (VTRS : NSDQ) |
|
|
| |
| • Company Description |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Number of Employees: 32,000 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $9.32 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 11,037,964 shares |
| Shares Outstanding: 1,173.68 (millions) |
| Market Capitalization: $10,938.72 (millions) |
| Beta: 0.89 |
| 52 Week High: $13.55 |
| 52 Week Low: $6.85 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
10.16% |
4.20% |
| 12 Week |
28.38% |
7.70% |
| Year To Date |
-25.14% |
-29.88% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Scott A. Smith - Chief Executive Officer
Melina Higgins - Chairperson
Mark Parrish - Vice Chairman
Theodora Mistras - Chief Financial Officer
W. Don Cornwell - Director
|
|
Peer Information
Viatris Inc. (CHCR)
Viatris Inc. (ESRX)
Viatris Inc. (MYDP)
Viatris Inc. (COR)
Viatris Inc. (GBCS)
Viatris Inc. (LAXAF)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 92556V106
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
|
|
Share - Related Items
Shares Outstanding: 1,173.68
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.89
Market Capitalization: $10,938.72 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 5.15% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.63 |
Indicated Annual Dividend: $0.48 |
| Current Fiscal Year EPS Consensus Estimate: $2.25 |
Payout Ratio: 0.19 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: 0.07 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: 05/23/2025 - $0.12 |
| Next EPS Report Date: 08/07/25 |
|
|
|
| |
